Disclosed is a 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide dihydrochloric acid salt represented by the structural formula depicted herein, a hydrate and solvate thereof. The disclosure also relates to a process of preparing the said hydrate, comprising: (a) reacting a first mixture comprising 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and water with at least two equivalents of hydrochloric acid in a solvent comprising water to form a second mixture and (b) combining the second mixture with methyl tert-butyl ether. Said salt, hydrate or solvate thereof is used for manufacturing a medicament for inhibiting the HGF/c-Met kinase signaling pathway in a cell, and are suitable for treating diseases selected from cancer, atherosclerosis, lung fibrosis, renal fibrosis and regeneration, liver disease, allergic disorder, inflammatory disease, autoimmune disorder, cerebrovascular disease, cardiovascular disease, or condition associated with organ transplantation.
